A sweeping new study of psychiatric and genetic records has the potential to change treatment for millions of psychiatric patients, finding that many conditions involve similar genes and may not need ...

The gene-editing market is projected to grow to $30.8 billion by 2032, highlighting investment potential. CRISPR Therapeutics, co-founder by Charpentier, gains momentum with FDA-approved therapies.

Those changes will be contested, in math as in other academic disciplines wrestling with AI’s impact. As AI models become a ...